Monitoring sedation depth with brain wave monitors during emergency procedures
| ISRCTN | ISRCTN55036065 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN55036065 |
| Sponsor | Atatürk University |
| Funder | Investigator initiated and funded |
- Submission date
- 06/10/2026
- Registration date
- 06/10/2026
- Last edited
- 06/10/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Furkan Akpinar
Public, Scientific, Principal investigator
Public, Scientific, Principal investigator
Hüseyin Avni Ulaş Neighborhood, Necip Fazıl Kısakürek Boulevard, C2-35 Block, No: 1-3G/15
Yıldızkent 1st Stage TOKİ Housing
Erzurum
25080
Türkiye
| 0009-0007-2089-5437 | |
| Phone | +90 05400750001 |
| furkan.akpinar1@saglik.gov.tr |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Active |
| Assignment | Parallel |
| Purpose | Device feasibility, Supportive care, Treatment |
| Scientific title | Assessment of procedural sedation depth with bispectral ındex in the emergency department: a randomized controlled, double-blind study |
| Study objectives | |
| Ethics approval(s) |
Approved 27/01/2022, Ataturk University Faculty of Medicine Clinical Research Ethics Committee (Ataturk Mah., Ataturk University Campus, Yakutiye, Erzurum, 25240, Türkiye; +90 (0)442 234 65 11; atatipetikkurul@gmail.com), ref: B.30.2.ATA.0.01.00/97 |
| Health condition(s) or problem(s) studied | Procedural sedation and analgesia in adult emergency department patients requiring procedural sedation for painful interventions. |
| Intervention | Eligible participants presenting to the emergency department who require procedural sedation and analgesia (PSA) are randomly allocated to one of two parallel groups using sealed, sequentially numbered envelopes: 1. Propofol-Fentanyl Group (Group 1): Participants receive intravenous (IV) propofol (maximum 1 mg/kg) combined with IV fentanyl (1 mcg/kg) 2. Propofol-Midazolam Group (Group 2 - Active Control): Participants receive intravenous (IV) propofol (maximum 1 mg/kg) combined with IV midazolam (0.05 mg/kg) To ensure blinding, study medications are prepared in identical sealed syringes by an independent provider. Half of the total calculated dose is administered as an initial IV bolus, followed by gradual titration at 2–3-minute intervals if target moderate sedation is not achieved, without exceeding the predetermined maximum dose limit. Before drug administration, single-use Bispectral Index Monitor (BIS; Aspect BIS Vista monitor / Aspect Medical Systems / Covidien-Medtronic) electrodes are placed on the forehead, and non-invasive hemodynamic monitoring (blood pressure, heart rate, pulse oximetry, and respiratory rate) is initiated. Baseline (minute 0) BIS and vital parameters are recorded. During the reduction procedure, BIS values, clinical sedation depth (assessed via verbal and tactile stimuli by a blinded observer), and vital signs are recorded minute by minute. Monitoring continues until participants return to their baseline cognitive levels (standardized as a BIS score ≥ 90 and return of orientation). |
| Intervention type | Drug/Device |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Propofol (propofol), fentanyl (fentanyl citrate), midazolam (midazolam hydrochloride), bispectral index monitor |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 01/01/2023 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 65 Years |
| Sex | All |
| Target sample size at registration | 90 |
| Total final enrolment | 91 |
| Key inclusion criteria | 1. Patients aged between 18 and 65 years 2. Presenting to the emergency department and requiring procedural sedation and analgesia (PSA) for closed reduction of extremity fractures or dislocations 3. Able to read, understand, and write in Turkish 4. American Society of Anesthesiologists (ASA) Physical Status Class I or Class II 5. Provision of written informed consent by the patient |
| Key exclusion criteria | 1. Patients younger than 18 or older than 65 years of age 2. Known allergy or hypersensitivity to any of the study medications (propofol, fentanyl, or midazolam) 3. American Society of Anesthesiologists (ASA) Physical Status Class ≥ 3 or ASA Class E according to ICAPS criteria 4. Uncontrolled diabetes mellitus, uncontrolled hypertension, or serious underlying cardiac or chronic pulmonary disease 5. Identified risk for difficult airway or high risk for pulmonary aspiration 6. Pregnancy or breastfeeding 7. Indications requiring minimal/dissociative sedation only or general anesthesia 8. Pre-existing cognitive dysfunction or inability to give informed consent 9. Impaired skin integrity in the frontal/forehead region preventing BIS sensor placement |
| Date of first enrolment | 01/02/2022 |
| Date of final enrolment | 07/11/2022 |
Locations
Countries of recruitment
- Türkiye
Study participating centres
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
06/10/2026: Study's existence confirmed by the Ataturk University Faculty of Medicine Clinical Research Ethics Committee.